British artificial intelligence drug discovery company founded in Oxford in 2012 as a spin-out from the University of Dundee, listed on the Nasdaq and combined with Recursion Pharmaceuticals in 2024. Used machine learning to design small molecules and to select and prioritise compounds, took several AI designed candidates into clinical trials in oncology and immunology, ran precision medicine work using patient tissue models, and worked with large pharmaceutical companies on discovery partnerships.
Keine Kommentare verfügbar.
Bewertung & Kommentar hinterlassen